Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02706730 · ClinicalTrials.gov registry record · Phase 3
A 6-Month Extension Study of OTO-104 in Meniere's Disease
A Phase 3 study, sponsored by Otonomy.
- Terminated
- Registry status
- Phase 3
- Development phase
- 189
- Enrollment target
NCT02706730: Clinical Trial Phase 3 study, sponsored by Otonomy.
NCT02706730 is a Phase 3 study that was terminated before completion, run by Otonomy. The registered enrollment target is 189 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02706730, a Phase 3 study, was terminated before completion, sponsored by Otonomy.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 189 participants
- Enrollment target
Study Summary
This is an open-label extension study of a single intratympanic injection of OTO-104 given every 3 months for a total of 2 injections. Subjects must have completed either Otonomy study 104-201102 (Phase 2b study of OTO-104) or 104-201506 (Phase 3 study of OTO-104) in order to be eligible for this open-label extension study.
Primary Outcome
Otoscopic examinations were conducted at each visit. It was considered important to understand if the tympanic perforation that resulted from the IT injection persisted at the end of study visit (Week 24 \[Month 6\]).
Interventions
- DRUG OTO-104
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2016-02 |
| Est. Completion | 2017-09 |
| Phase | Phase 3 |
Why NCT02706730 stopped before completion
NCT02706730 is an interventional study that assigns participants to a tested intervention. The registered 189 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 1 intervention - of which OTO-104 is the first listed.
NCT02706730 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02706730 about?
NCT02706730 is a clinical study titled "A 6-Month Extension Study of OTO-104 in Meniere's Disease". This is an open-label extension study of a single intratympanic injection of OTO-104 given every 3 months for a total of 2 injections. Subjects must have completed either Otonomy study 104-201102 (Phase 2b study of OTO-104) or 104-201506 (Phase 3 study of OTO-104) in order to be eligible for this op...
What is the current status of trial NCT02706730?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 189 participants. The study started on 2016-02. Estimated completion is 2017-09.
What interventions are being tested in trial NCT02706730?
The interventions under investigation include: OTO-104 (DRUG).
Who is sponsoring clinical trial NCT02706730?
This trial is sponsored by Otonomy, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02706730's enrollment target sits among peer trials
189 1408th of 2000 higher than 593 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02734537 · 189 participants · Phase 2
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- NCT05058651 · 189 participants · Phase 2
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
- NCT05673408 · 189 participants
NIBP Validation Study
- NCT05994209 · 189 participants · Phase 1
Testing the Feasibility and Acceptability of Social Media and Digital Therapeutics to Decrease Vaping Behaviors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia